<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Genes Environ</journal-id><journal-id journal-id-type="iso-abbrev">Genes Environ</journal-id><journal-id journal-id-type="pmc-domain-id">3026</journal-id><journal-id journal-id-type="pmc-domain">genv</journal-id><journal-title-group><journal-title>Genes and Environment</journal-title></journal-title-group><issn pub-type="ppub">1880-7046</issn><issn pub-type="epub">1880-7062</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5219678</article-id><article-id pub-id-type="pmcid-ver">PMC5219678.1</article-id><article-id pub-id-type="pmcaid">5219678</article-id><article-id pub-id-type="pmcaiid">5219678</article-id><article-id pub-id-type="pmid">28074113</article-id><article-id pub-id-type="doi">10.1186/s41021-016-0066-4</article-id><article-id pub-id-type="publisher-id">66</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Genetic polymorphisms of human cytochrome P450 CYP1A1 in an Egyptian population and tobacco-induced lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ezzeldin</surname><given-names initials="N">Nada</given-names></name><address><email>nada.ezzeldin@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>El-Lebedy</surname><given-names initials="D">Dalia</given-names></name><address><email>d_lebedy@yahoo.co.uk</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Darwish</surname><given-names initials="A">Amira</given-names></name><address><email>amiradd@yahoo.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>El-Bastawisy</surname><given-names initials="A">Ahmed</given-names></name><address><email>a_s_basta@hotmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hassan</surname><given-names initials="M">Mirhane</given-names></name><address><email>mirhanehassan@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abd El-Aziz</surname><given-names initials="S">Shereen</given-names></name><address><email>sherryhamdy4@yahoo.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abdel-Hamid</surname><given-names initials="M">Mohamed</given-names></name><address><email>mohamadnrc@hotmail.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saad-Hussein</surname><given-names initials="A">Amal</given-names></name><address><email>amel_h@hotmail.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label>Chest Diseases, National Research Center, Cairo, Egypt </aff><aff id="Aff2"><label>2</label>Department of Clinical and Chemical Pathology, National Research Center, Cairo, Egypt </aff><aff id="Aff3"><label>3</label>Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt </aff><aff id="Aff4"><label>4</label>Medical Molecular Genetics, National Research Center, Cairo, Egypt </aff><aff id="Aff5"><label>5</label>Department of Environmental Health and Preventive Medicine, National Research Center, Cairo, Egypt </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>1</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>39</volume><issue-id pub-id-type="pmc-issue-id">273926</issue-id><elocation-id>7</elocation-id><history><date date-type="received"><day>28</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>8</day><month>12</month><year>2016</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>01</month><year>2017</year></date></event><event event-type="pmc-live"><date><day>10</day><month>01</month><year>2017</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2017-01-12 21:11:35.087"><day>12</day><month>01</month><year>2017</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41021_2016_Article_66.pdf"/><abstract id="Abs1"><sec><title>Background</title><p>Cytochrome P450 CYP1A1 helps detoxify the potential carcinogens in tobacco smoke, it was reported that polymorphisms in the coding gene result in variation in the expression and activity levels which alter metabolism and clearance of carcinogens and therefore modify cancer risk. In this work, we aimed to identify <italic toggle="yes">CYP1A1</italic> gene polymorphisms associated with lung cancer in Egyptian population and to examine the interaction effect with Tobacco smoking in modulating disease risk.</p></sec><sec><title>Methods</title><p>A case&#8211;control study was conducted on 150 unrelated lung cancer patients and 150 unrelated control subjects. Genomic DNA was extracted and sequencing analysis of <italic toggle="yes">CYP1A1</italic> gene was performed on ABI PRISM 3100 genetic analyzer.</p></sec><sec><title>Results</title><p>Three variants in <italic toggle="yes">CYP1A1</italic> gene were identified in heterozygous forms in lung cancer patients <italic toggle="yes">I462V, T461N</italic> and <italic toggle="yes">I286T</italic>. A combined variant <italic toggle="yes">T461N/ I462V</italic> associated with lung cancer and those who carried this variant were 2-times more likely to develop lung cancer (OR&#8201;=&#8201;2.03, 95% CI&#8201;=&#8201;1.81-2.29, <italic toggle="yes">P</italic>&#8201;=&#8201;0.04), specially the non-small cell type (NSCLC) (OR&#8201;=&#8201;2.20, 95% CI&#8201;=&#8201;1.93&#8211;2.50, <italic toggle="yes">P</italic>&#8201;=&#8201;0.02). Wild type was more frequent among smoker controls (83.3%) compared to smoker lung cancer patients (54.8%), <italic toggle="yes">P</italic>&#8201;=&#8201;0.03. Association studies to examine the interaction effect of identified variants with Tobacco smoking in modulating disease risk showed no significant associations. Identified polymorphisms showed no significant implication on the stage or the prognosis of the disease.</p></sec><sec><title>Conclusion</title><p>Our findings support that <italic toggle="yes">CYP1A1</italic> polymorphisms play a role in the pathogenesis of lung cancer. In Egyptian population, <italic toggle="yes">CYP1A1 I462V, T461N and I286T</italic> variants were identified among lung cancer patients and combined <italic toggle="yes">T461N/ I462V</italic> was a risk variant for NSCLC in non smokers.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Lung cancer</kwd><kwd><italic toggle="yes">CYP1A1</italic></kwd><kwd>Polymorphisms</kwd><kwd>Tobacco smoking</kwd></kwd-group><funding-group><award-group><funding-source><institution>Science and Technology Development Fund of Egypt (STDF)</institution></funding-source><award-id>project ID 5016</award-id><principal-award-recipient><name name-style="western"><surname>Ezzeldin</surname><given-names>Nada</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Lung cancer progression is characterized by cumulative alterations in key molecules involved in the cell cycle, signaling and angiogenesis pathways. Most lung cancer patients demonstrate chromosomal abnormalities at the site of tumor suppressor genes or have mutations in known oncogenes [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>In the laboratory, chemicals in tobacco reduce the capacity to repair DNA damage in cells from lung cancer patients than cells from normal individuals [<xref ref-type="bibr" rid="CR2">2</xref>]. As many smokers do not develop lung cancer, it is likely that inherited factors influence the effects of tobacco. There is a considerable interest in variants of genes that help detoxify the carcinogens in tobacco smoke, such as members of the cytochrome P450 (<italic toggle="yes">CYP</italic>), glutathione S-transferase (<italic toggle="yes">GST</italic>) and N-acetyltransferase (<italic toggle="yes">NAT)</italic> gene families [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>Scientists have identified 57 human <italic toggle="yes">CYP</italic> genes and 33 pseudo genes divided into 18 families and 42 subfamilies. Now <italic toggle="yes">CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5</italic> and other gene polymorphisms have been confirmed and specific metabolic enzyme phenotypes differ with regions and races [<xref ref-type="bibr" rid="CR4">4</xref>]. <italic toggle="yes">CYP</italic> gene changes can cause increased activity of the enzyme, decreased activity or even inactivity. In addition, mutations at the substrate recognition sites may lead to changes in enzyme specificity [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>CYP1A1 plays a major role as a carcinogen activating enzyme within the CYP system. Unlike most CYP enzymes, CYP1A1 expression is mainly found in extra hepatic tissues, including the lung, where it metabolizes and is markedly induced by polycyclic aromatic hydrocarbons (PAHs) [<xref ref-type="bibr" rid="CR6">6</xref>]. Elevated CYP1A1 inducibility is associated with pulmonary PAH-related DNA adduction [<xref ref-type="bibr" rid="CR7">7</xref>] and high lung cancer risk [<xref ref-type="bibr" rid="CR8">8</xref>]. Both CYP1A1 expression and the formation of these PAH-DNA adducts in human lung tissue are highly variable [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>], possibly due to differing exposure to environmental factors and to genetic polymorphisms affecting the <italic toggle="yes">CYP1A1</italic> gene locus [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>The first variant allele identified was <italic toggle="yes">CYP1A1*2A</italic> (MspI or m1 polymorphism) and is found in 5% of Caucasians [<xref ref-type="bibr" rid="CR13">13</xref>]. <italic toggle="yes">CYP1A1*2C</italic> (Ile462Val or m2 polymorphism) is rare in Caucasians and is usually detected with <italic toggle="yes">CYP1A1*2A</italic> [<xref ref-type="bibr" rid="CR14">14</xref>]. The combination of both variants is referred to as <italic toggle="yes">CYP1A1*2B. CYP1A1*3</italic>, consisting of a T3205C base change (m3), seems to show enhanced enzyme activity, although it is extremely uncommon in Caucasians [<xref ref-type="bibr" rid="CR13">13</xref>]. Finally, <italic toggle="yes">CYP1A1*4</italic>, a Thr461Asn (m4) amino acid change, detected in Caucasians with a frequency of roughly 3%, has also been related to greater enzyme catalytic efficiency [<xref ref-type="bibr" rid="CR15">15</xref>]. These <italic toggle="yes">CYP1A1</italic> polymorphisms have been extensively studied with regard to risk of lung cancer. However, whereas some studies report increased risk in the presence of some of the mutations [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], there are many other contradictory results due to ethnic differences [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p><p>The aim of this work is to identify CYP1A1 gene polymorphisms associated with lung cancer in Egyptian population and to examine the interaction effect with Tobacco smoking in modulating disease risk.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Subjects</title><p>This work was collaboration between National Cancer Institute (NCI) and National Research Center (NRC), Cairo, Egypt. A case&#8211;control study was conducted on 150 unrelated adult patients with primary lung cancer and 150 unrelated controls. Patients were presented to NCI from different governorates of Egypt; Cairo, Giza, Qalyubia, Sharqia, Monufia, Kafr El-Sheikh, Minya, Faiyum, Asyut, Sohag and Qena. All subjects included in the study were interviewed to fill a medical questionnaire with special consideration to the lifetime history of tobacco use, residence, occupational history and family history of cancer. Thorough clinical examination and chest radiography were applied. Blood sample was obtained from each subject for sequencing analysis of the human CYP1A1 gene. Sample for histopathology examination of cancer was obtained from each patient either by open biopsy or via bronchoscopy. The exclusion criteria included previous history of cancer, metastasized cancer from other organs, patients with pulmonary fibrosis, acute interstitial pneumonia and previous radiotherapy or chemotherapy or receiving any anti-cancer treatment before enrollment in the study. The study was approved by the ethics committee of the National Research Center. All subjects were aware by the nature of the study and gave a written informed consent.</p></sec></sec><sec id="Sec4"><title>Methodology</title><sec id="Sec5"><title>DNA extraction</title><p>Genomic DNA was extracted from blood samples obtained from 150 controls and 150 lung cancer patients using QIAamp DNA extraction kit (Qiagen Hilden, Germany, Cat no. 51304) according to the manufacturer's instructions.</p></sec><sec id="Sec6"><title>Sequence analysis of the CYP1A1 gene</title><p>The sequence of the human <italic toggle="yes">CYP1A1</italic> gene described in the GenBank (accession number <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="X02612">X02612</ext-link>) was used as a reference. The primers used for the amplification and the direct sequencing of all seven exons and exon-intron junctions of the gene are shown in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. PCR for each fragment of <italic toggle="yes">CYP1A1</italic> gene was conducted in a 25&#160;&#956;l reaction mixture containing 100&#160;ng of genomic DNA, 20 pmol of each primer and 12.5&#160;&#956;l of AmpliTaq Gold 360 Master Mix (Applied BioSystems, Foster City, CA, USA). PCR cycling conditions consisted of initial denaturation at 94&#160;&#176;C for 5&#160;min, followed by 30&#160;cycles of denaturation at 94&#160;&#176;C for 30s, annealing at 60&#160;&#176;C for 30s and extension at 72&#160;&#176;C for 30s, followed by a final extension of 5&#160;min at 72&#160;&#176;C. PCR products were checked first on 2% agarose gel for successful amplification (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>) and was further purified using PureLink Quick PCR Purification Kit (Invitrogen, Germany). The purified PCR products were directly sequenced in both directions using the Big Dye Termination kit (Applied Biosystems, Foster City, CA, USA) and sequences were determined using ABI PRISM 3100 genetic analyzer (Applied Biosystems).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Primers used for amplification and direct sequencing analysis of the human CYP1A1 gene</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Primers</th><th colspan="1" rowspan="1">Primer sequence (5&#8242;&#8211;3&#8242; orientation)</th><th colspan="1" rowspan="1">Location</th><th colspan="1" rowspan="1">Amplified exon</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1A1 ex1-S</td><td colspan="1" rowspan="1">CCGAGTCCTGGTAGGCTGTA</td><td colspan="1" rowspan="1">5&#8242;-fanking</td><td rowspan="2" colspan="1">Exon 1</td></tr><tr><td colspan="1" rowspan="1">1A1 ex1-A</td><td colspan="1" rowspan="1">CCTGCAGTTGGCAATCTGTC</td><td colspan="1" rowspan="1">intron 1</td></tr><tr><td colspan="1" rowspan="1">1A1 ex2-S</td><td colspan="1" rowspan="1">CCCACAGTGGTAGTTCAACA</td><td colspan="1" rowspan="1">intron 1</td><td rowspan="2" colspan="1">Exon 2</td></tr><tr><td colspan="1" rowspan="1">1A1 ex2-A</td><td colspan="1" rowspan="1">CCCTGCCAAGGAAGAAGACT</td><td colspan="1" rowspan="1">intron 2</td></tr><tr><td colspan="1" rowspan="1">1A1 ex3-S</td><td colspan="1" rowspan="1">AGAGCCTTGCAGAGGCAGAG</td><td colspan="1" rowspan="1">intron 2</td><td rowspan="2" colspan="1">Exons 3&#8211;6</td></tr><tr><td colspan="1" rowspan="1">1A1 ex6-A</td><td colspan="1" rowspan="1">GGCAATGGTCTCACCGATAC</td><td colspan="1" rowspan="1">exon 6</td></tr><tr><td colspan="1" rowspan="1">1A1 I462V-S</td><td colspan="1" rowspan="1">GCTGCTTGCCTGTCCTCTAT</td><td colspan="1" rowspan="1">intron 6</td><td rowspan="2" colspan="1">Exon 7a</td></tr><tr><td colspan="1" rowspan="1">1A1 I462V-A</td><td colspan="1" rowspan="1">AGGCATGCTTCATGGTTAGC</td><td colspan="1" rowspan="1">exon 7</td></tr><tr><td colspan="1" rowspan="1">1A1 ex7-S</td><td colspan="1" rowspan="1">AGCTATGGGTCAACCCATCT</td><td colspan="1" rowspan="1">exon 7</td><td rowspan="2" colspan="1">Exon 7b</td></tr><tr><td colspan="1" rowspan="1">1A1 ex7-A</td><td colspan="1" rowspan="1">TCTTCTTCCTCCCTACAGTA</td><td colspan="1" rowspan="1">intron 7</td></tr></tbody></table></table-wrap>
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>2% agarose gel illustrating the amplification of CYP1A1 gene in two patients. Lanes 1 and 6: amplification of exon 1 (1153-bp). Lanes 2 and 7: amplification of exon 2 (1180-bp). Lane 3 and 8: amplification of exons 3&#8211;6 (1233-bp). Lanes 4 and 9: amplification of exon 7a (349-bp). Lanes 5 and 10: amplification of exon 7b (1330-bp). M: Size marker (PhiX174 DNA/HaeIII digest)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="41021_2016_66_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec7"><title>Statistical analysis</title><p>Data were analyzed using SPSS version 18.0 (Chicago, IL, USA). Data were expressed as number and percentage of total for categorical variables. Chi-square test (&#967;<sup>2</sup>) was used to compare the distribution of CYP1A1 genotypes between groups. Likelihood ratio was used when the expected count was less than 5 in more than 20% of the cells. The associations between genotype and risk of lung cancer were estimated by odds ratio (OR) and 95% confidence interval (95% CI) using logistic regression models. The ORs were adjusted for age, smoking status, and pack-years. <italic toggle="yes">P</italic>-value &lt;0.05 was considered significant.</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><p>The study included 300 subjects; 150 unrelated lung cancer patients and 150 unrelated control subjects. A statistical significant age difference was found between controls (mean 43.3&#8201;&#177;&#8201;11.1&#160;years) and patients (mean 56.7&#8201;&#177;&#8201;9.79&#160;years) (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), denoting that older age is associated with higher risk of lung cancer. There was a statistical significant difference in gender between the two groups with 51.3% females and 48.7% males in control group vs. 24% females and 76% males in patients group (X<sup>2</sup>&#8201;=&#8201;25.82, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.0001), with 3.5-times increased risk to develop lung cancer in males than in females (OR&#8201;=&#8201;3.49, CI: 2.13&#8211;5.69).</p><p>Mean pack-years was significantly higher in patients (21.4&#8201;&#177;&#8201;2.25) than in controls (4.0&#8201;&#177;&#8201;0.77). Smoking habit was significantly higher among patients (X<sup>2</sup>&#8201;=&#8201;56.88, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.0001), with an odd ration of 6.69 (CI: 3.99&#8211;11.20) denoting a higher risk to develop lung cancer in smokers by 6.7 times the non-smokers.</p><p>Our sequencing analysis of <italic toggle="yes">CYP1A1</italic> gene identified 2 variants in exon7 in control subjects; <italic toggle="yes">CYP1A1*4</italic> 1382C&#8201;&gt;&#8201;A (T461N) (<italic toggle="yes">n</italic>&#8201;=&#8201;33) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) and <italic toggle="yes">CYP1A1*2C</italic> 1384A&#8201;&gt;&#8201;G (I462V) (<italic toggle="yes">n</italic>&#8201;=&#8201;19) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). In lung cancer patients, 3 variants were identified, CYP1A1*2C (<italic toggle="yes">n</italic>&#8201;=&#8201;17), <italic toggle="yes">CYP1A1*4</italic> (<italic toggle="yes">n</italic>&#8201;=&#8201;46) and combined <italic toggle="yes">CYP1A1*2C/ CYP1A1*4</italic> (<italic toggle="yes">n</italic>&#8201;=&#8201;4). The very low frequent variant in the database CYP1A1 857&#160;T&#8201;&gt;&#8201;C (I286T), which was found only 2 times in thousands of human genomes, has been detected in exons 3&#8211;6 of the <italic toggle="yes">CYP1A1</italic> gene in a non-smoker adenocarcinoma case (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). All identified variants were detected in the heterozygous form.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Portion of the sequencing phoregram of exon7 of CYP1A1 gene showing the c.1382C&#8201;&gt;&#8201;A (T461N) polymorphism. The <italic toggle="yes">arrow</italic> indicates the site of the variant nucleotide position</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="41021_2016_66_Fig2_HTML.jpg"/></fig>
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Portion of the sequencing phoregrams of exon 7 of CYP1A1 gene showing the c.1384A&#8201;&gt;&#8201;G (I462V) polymorphism. The <italic toggle="yes">arrow</italic> indicates the site of the variant nucleotide position</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="41021_2016_66_Fig3_HTML.jpg"/></fig>
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Portion of the sequencing phoregram of exons 3&#8211;6 of CYP1A1 gene showing c.857&#160;T&#8201;&gt;&#8201;C (I286T) polymorphism found in only one subject. The <italic toggle="yes">arrow</italic> indicates the site of the variant nucleotide position</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="41021_2016_66_Fig4_HTML.jpg"/></fig>
</p><p>There was no significant difference between controls and lung cancer patients regarding the frequency of identified <italic toggle="yes">CYP1A1</italic> variants, except for the combined variants <italic toggle="yes">CYP1A1*2C/ CYP1A1*4</italic> which associated with 2-times higher risk of lung cancer (OR&#8201;=&#8201;2.03, 95% C.I:1.81&#8211;2.29, <italic toggle="yes">P</italic>&#8201;=&#8201;0.04), specially the non-small cell type (NSCLC) (OR&#8201;=&#8201;2.20, 95% C.I: 1.93&#8211;2.50, <italic toggle="yes">P</italic> value&#8201;=&#8201;0.02) (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>) with no significant difference between the pathological subtypes of NSCLC (<italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Frequency of CYP1A1 variants among lung cancer patients and control</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">CYP1A1</th><th colspan="1" rowspan="1">Control<sup>a</sup>
</th><th colspan="1" rowspan="1">Cases<sup>a</sup>
</th><th colspan="1" rowspan="1">OR (95% CI)</th><th colspan="1" rowspan="1">NSCLC<sup>a</sup>
</th><th colspan="1" rowspan="1">OR (95% CI)</th><th colspan="1" rowspan="1">SCLC<sup>a</sup>
</th><th colspan="1" rowspan="1">OR (95% CI)</th></tr><tr><th colspan="1" rowspan="1">Variant</th><th colspan="1" rowspan="1">
<italic toggle="yes">n</italic>=150</th><th colspan="1" rowspan="1">
<italic toggle="yes">n</italic>=149<sup>b</sup>
</th><th colspan="1" rowspan="1">
<italic toggle="yes">P</italic>- value</th><th colspan="1" rowspan="1">
<italic toggle="yes">n</italic>=129</th><th colspan="1" rowspan="1">
<italic toggle="yes">P</italic> value</th><th colspan="1" rowspan="1">
<italic toggle="yes">n</italic>=20</th><th colspan="1" rowspan="1">
<italic toggle="yes">P</italic>- value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">CYP1A1*2C</td><td colspan="1" rowspan="1">19(12.7)</td><td colspan="1" rowspan="1">17(11.4)</td><td colspan="1" rowspan="1">1.126(0.56&#8211;2.26)<break/>0.7</td><td colspan="1" rowspan="1">13(10.1)</td><td colspan="1" rowspan="1">0.77(0.37&#8211;1.63)<break/>0.4</td><td colspan="1" rowspan="1">4(20)</td><td colspan="1" rowspan="1">1.72(0.52&#8211;5.70)<break/>0.3</td></tr><tr><td colspan="1" rowspan="1">CYP1A1*4</td><td colspan="1" rowspan="1">33(22)</td><td colspan="1" rowspan="1">46(30.9)</td><td colspan="1" rowspan="1">0.63(0.38&#8211;1.06)<break/>0.08</td><td colspan="1" rowspan="1">41(31.8)</td><td colspan="1" rowspan="1">1.65(0.97&#8211;2.82)<break/>0.06</td><td colspan="1" rowspan="1">5(25)</td><td colspan="1" rowspan="1">1.18 (0.40&#8211;3.49)<break/>0.7</td></tr><tr><td colspan="1" rowspan="1">CYP1A1*2C/*4</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">4(2.7)</td><td colspan="1" rowspan="1">2.03(1.81&#8211;2.29)<break/>0.04<sup>c</sup>
</td><td colspan="1" rowspan="1">4(3.1)</td><td colspan="1" rowspan="1">2.20(1.93&#8211;2.50)<break/>0.02<sup>c</sup>
</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">CYP1A1*1<break/>(wild type)</td><td colspan="1" rowspan="1">98(65.3)</td><td colspan="1" rowspan="1">82(55)</td><td colspan="1" rowspan="1">0.65(0.41&#8211;1.04)<break/>0.07</td><td colspan="1" rowspan="1">71(55)</td><td colspan="1" rowspan="1">0.11(&#8722;0.01&#8211;0.23)<break/>0.07</td><td colspan="1" rowspan="1">11(55)</td><td colspan="1" rowspan="1">1.54(0.60, 3.96)<break/>0.3</td></tr></tbody></table><table-wrap-foot><p>
<italic toggle="yes">SCLC</italic> small cell lung cancer, <italic toggle="yes">NSCLC</italic> non-small cell lung cancer</p><p>
<sup>a</sup>Data presented as N (%)</p><p>
<sup>b</sup>The case carrying rare CYP1A1 857&#160;T&#8201;&gt;&#8201;C (I286T) variant was excluded from the statistical analysis</p><p>
<sup>c</sup>significant <italic toggle="yes">p</italic>
</p></table-wrap-foot></table-wrap>
</p><p>There was statistical significant difference in the distribution of <italic toggle="yes">CYP1A1</italic> variants in relation to smoking habit among lung cancer patients and control subjects. The wild type gene was the most frequent among smoker controls compared to non-smoker controls and lung cancer patients (<italic toggle="yes">P</italic>&#8201;=&#8201;0.03) (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Association studies of <italic toggle="yes">CYP1A1</italic> polymorphisms and smoking with susceptibility to lung cancer showed no significant association with disease risk (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>). No significant association of <italic toggle="yes">CYP1A1</italic> polymorphisms and pack year with susceptibility to lung cancer (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>). Identified polymorphisms showed no significant implication on the stage or the prognosis of the disease (Tables&#160;<xref rid="Tab6" ref-type="table">6</xref> and <xref rid="Tab7" ref-type="table">7</xref>).<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Frequency of CYP1A1 variants in relation to smoking habit in patients and control</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2">CYP1A1 Variant</th><th colspan="2" rowspan="1">Control</th><th colspan="2" rowspan="1">Patients</th><th rowspan="2" colspan="1">Chi-square</th><th rowspan="2" colspan="1">
<italic toggle="yes">P</italic>-value</th></tr><tr><th colspan="1" rowspan="1">Non-smoker</th><th colspan="1" rowspan="1">Smoker</th><th colspan="1" rowspan="1">Non-smoker</th><th colspan="1" rowspan="1">Smoker</th></tr><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">
<italic toggle="yes">N</italic>&#8201;=&#8201;120</th><th colspan="1" rowspan="1">
<italic toggle="yes">N</italic>&#8201;=&#8201;30</th><th colspan="1" rowspan="1">
<italic toggle="yes">N</italic>&#8201;=&#8201;56</th><th colspan="1" rowspan="1">
<italic toggle="yes">N</italic>&#8201;=&#8201;93</th><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/></tr></thead><tbody><tr><td colspan="1" rowspan="1">CYP1A1*2C</td><td colspan="1" rowspan="1">N (%)</td><td colspan="1" rowspan="1">18 (15)</td><td colspan="1" rowspan="1">1 (3.3)</td><td colspan="1" rowspan="1">7 (12.5)</td><td colspan="1" rowspan="1">10 (10.8)</td><td rowspan="4" colspan="1">18.9</td><td rowspan="4" colspan="1">0.03<sup>a</sup>
</td></tr><tr><td colspan="1" rowspan="1">CYP1A1*4</td><td colspan="1" rowspan="1">N (%)</td><td colspan="1" rowspan="1">29(24.2)</td><td colspan="1" rowspan="1">4 (13.3)</td><td colspan="1" rowspan="1">15 (26.8)</td><td colspan="1" rowspan="1">31 (33.3)</td></tr><tr><td colspan="1" rowspan="1">CYP1A1*2C/*4</td><td colspan="1" rowspan="1">N (%)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">3 (5.4)</td><td colspan="1" rowspan="1">1 (1.1)</td></tr><tr><td colspan="1" rowspan="1">CYP1A1*1 (wild type)</td><td colspan="1" rowspan="1">N (%)</td><td colspan="1" rowspan="1">73 (60.8)</td><td colspan="1" rowspan="1">25 (83.3)<sup>a</sup>
</td><td colspan="1" rowspan="1">31 (55.4)</td><td colspan="1" rowspan="1">51 (54.8)</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Significant <italic toggle="yes">P</italic>
</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Association of CYP1A1 polymorphisms and smoking with lung cancer risk</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" colspan="1">CYP1A1 Variant</th><th colspan="1" rowspan="1">Non-smokers</th><th colspan="1" rowspan="1">Smokers</th><th rowspan="3" colspan="1">OR</th><th rowspan="3" colspan="1">95% CI</th><th rowspan="3" colspan="1">
<italic toggle="yes">P</italic>-value</th></tr><tr><th colspan="1" rowspan="1">
<italic toggle="yes">N</italic>&#8201;=&#8201;56</th><th colspan="1" rowspan="1">
<italic toggle="yes">N</italic>&#8201;=&#8201;93</th></tr><tr><th colspan="1" rowspan="1">N (%)</th><th colspan="1" rowspan="1">N (%)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">CYP1A1*2C</td><td colspan="1" rowspan="1">7 (12.5)</td><td colspan="1" rowspan="1">10 (10.8)</td><td char="." align="char" colspan="1" rowspan="1">1.19</td><td colspan="1" rowspan="1">(0.42&#8211;3.32)</td><td char="." align="char" colspan="1" rowspan="1">0.75</td></tr><tr><td colspan="1" rowspan="1">CYP1A1*4</td><td colspan="1" rowspan="1">15 (26.8)</td><td colspan="1" rowspan="1">31 (33.3)</td><td char="." align="char" colspan="1" rowspan="1">0.73</td><td colspan="1" rowspan="1">(0.35&#8211;1.52)</td><td char="." align="char" colspan="1" rowspan="1">0.20</td></tr><tr><td colspan="1" rowspan="1">CYP1A1*2C/*4</td><td colspan="1" rowspan="1">3 (5.4)</td><td colspan="1" rowspan="1">1 (1.1)</td><td char="." align="char" colspan="1" rowspan="1">5.21</td><td colspan="1" rowspan="1">(0.53&#8211;51.3)</td><td char="." align="char" colspan="1" rowspan="1">0.12</td></tr><tr><td colspan="1" rowspan="1">CYP1A1*1 (wild type)</td><td colspan="1" rowspan="1">31 (55.4)</td><td colspan="1" rowspan="1">51 (54.8)</td><td char="." align="char" colspan="1" rowspan="1">0.98</td><td colspan="1" rowspan="1">(0.50&#8211;1.91)</td><td char="." align="char" colspan="1" rowspan="1">0.95</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Distribution of CYP1A1 polymorphisms in heavy (pack year&#8201;&#8805;&#8201;20) vs. light (pack year&#8201;&lt;&#8201;20) smoking in lung cancer patients and control</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="4" colspan="2">CYP1A1 variant</th><th colspan="4" rowspan="1">Smoking heaviness</th><th rowspan="2" colspan="2">Likelihood ratio</th></tr><tr><th colspan="2" rowspan="1">Control</th><th colspan="2" rowspan="1">patients</th></tr><tr><th colspan="1" rowspan="1">Light</th><th colspan="1" rowspan="1">heavy</th><th colspan="1" rowspan="1">Light</th><th colspan="1" rowspan="1">heavy</th><th rowspan="2" colspan="1">ratio</th><th rowspan="2" colspan="1">
<italic toggle="yes">P</italic>-value</th></tr><tr><th colspan="1" rowspan="1">
<italic toggle="yes">N</italic>&#8201;=&#8201;16</th><th colspan="1" rowspan="1">
<italic toggle="yes">N</italic>&#8201;=&#8201;14</th><th colspan="1" rowspan="1">
<italic toggle="yes">N</italic>&#8201;=&#8201;37</th><th colspan="1" rowspan="1">
<italic toggle="yes">N</italic>&#8201;=&#8201;56</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">CYP1A1*2C</td><td colspan="1" rowspan="1">N (%)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">1 (7)</td><td colspan="1" rowspan="1">1 (2.7)</td><td colspan="1" rowspan="1">9 (16.1)</td><td rowspan="4" colspan="1">15.86</td><td rowspan="4" colspan="1">0.07</td></tr><tr><td colspan="1" rowspan="1">CYP1A1*4</td><td colspan="1" rowspan="1">N (%)</td><td colspan="1" rowspan="1">1 (6.3)</td><td colspan="1" rowspan="1">3 (21.4)</td><td colspan="1" rowspan="1">12 (32.4)</td><td colspan="1" rowspan="1">19 (33.9)</td></tr><tr><td colspan="1" rowspan="1">CYP1A1*2C/*4</td><td colspan="1" rowspan="1">N (%)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">1 (1.8)</td></tr><tr><td colspan="1" rowspan="1">wild type</td><td colspan="1" rowspan="1">N (%)</td><td colspan="1" rowspan="1">15 (93.8)</td><td colspan="1" rowspan="1">10 (71.4)</td><td colspan="1" rowspan="1">24 (64.9)</td><td colspan="1" rowspan="1">27 (48.2)</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table 6</label><caption><p>Effect of CYP1A1 polymorphisms on lung cancer staging</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" colspan="3">CYP1A1 gene variant</th><th colspan="3" rowspan="1">Stage</th><th rowspan="3" colspan="1">Likelihood</th><th rowspan="3" colspan="1">
<italic toggle="yes">P</italic>-value</th></tr><tr><th colspan="1" rowspan="1">II</th><th colspan="1" rowspan="1">III</th><th colspan="1" rowspan="1">IV</th></tr><tr><th colspan="1" rowspan="1">
<italic toggle="yes">N</italic>&#8201;=&#8201;25</th><th colspan="1" rowspan="1">
<italic toggle="yes">N</italic>&#8201;=&#8201;44</th><th colspan="1" rowspan="1">
<italic toggle="yes">N</italic>&#8201;=&#8201;80</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">CYP1A1*2C</td><td colspan="1" rowspan="1">N (%)</td><td colspan="1" rowspan="1">19 (4)</td><td colspan="1" rowspan="1">5 (11)</td><td colspan="1" rowspan="1">11(14)</td><td rowspan="4" colspan="1">10.22</td><td rowspan="4" colspan="1">0.333</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">CYP1A1*4</td><td colspan="1" rowspan="1">N (%)</td><td colspan="1" rowspan="1">9 (36)</td><td colspan="1" rowspan="1">15 (34)</td><td colspan="1" rowspan="1">22 (28)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">CYP1A1*2C/*4</td><td colspan="1" rowspan="1">N (%)</td><td colspan="1" rowspan="1">1 (4)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">3 (4)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">CYP1A1*1 (wild type)</td><td colspan="1" rowspan="1">N (%)</td><td colspan="1" rowspan="1">14 (56)</td><td colspan="1" rowspan="1">24 (55)</td><td colspan="1" rowspan="1">44 (55)</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab7" position="float" orientation="portrait"><label>Table 7</label><caption><p>Effects of CYP1A1 polymorphisms on disease prognosis of available follow up cases</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" colspan="1">CYP1A1 variant</th><th colspan="6" rowspan="1">Response (n&#8201;=&#8201;22)</th><th rowspan="3" colspan="1">Chi</th><th rowspan="3" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><th colspan="1" rowspan="1">Complete response</th><th colspan="1" rowspan="1">Partial response</th><th colspan="1" rowspan="1">Progression</th><th colspan="1" rowspan="1">Refractory disease</th><th colspan="1" rowspan="1">Regression</th><th colspan="1" rowspan="1">Stable disease</th></tr><tr><th colspan="1" rowspan="1">N (%)</th><th colspan="1" rowspan="1">N (%)</th><th colspan="1" rowspan="1">N (%)</th><th colspan="1" rowspan="1">N (%)</th><th colspan="1" rowspan="1">N (%)</th><th colspan="1" rowspan="1">N (%)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">CYP1A1*2C</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">CYP1A1*4</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">2 (22.2)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">1 (25.0)</td><td colspan="1" rowspan="1">1 (25.0)</td><td colspan="1" rowspan="1">6.8</td><td colspan="1" rowspan="1">0.33</td></tr><tr><td colspan="1" rowspan="1">CYP1A1*2C/*4</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">1 (11.1)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">0 (0)</td><td colspan="1" rowspan="1">3.08</td><td colspan="1" rowspan="1">0.79</td></tr><tr><td colspan="1" rowspan="1">wild type</td><td colspan="1" rowspan="1">2 (100)</td><td colspan="1" rowspan="1">2 (100)</td><td colspan="1" rowspan="1">6 (66.7)</td><td colspan="1" rowspan="1">1 9(100)</td><td colspan="1" rowspan="1">3 (75.0)</td><td colspan="1" rowspan="1">3 (75.0)</td><td colspan="1" rowspan="1">12.2</td><td colspan="1" rowspan="1">0.052</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec9" sec-type="discussion"><title>Discussion</title><p>
<italic toggle="yes">CYP1A1</italic> is a polymorphic gene located at 15q24.1 with 7 exons and 6 introns. In addition to the wild-type <italic toggle="yes">(CYP1A1*1</italic>), 10 variant alleles have been identified [<xref ref-type="bibr" rid="CR7">7</xref>]. Variants <italic toggle="yes">CYP1A1*2A, CYP1A1*2C, CYP1A1*3 and CYP1A1*4</italic> with trivial names <italic toggle="yes">m1, m2, m3 and m4</italic>; respectively were the most commonly studied for cancer link [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p><p>About 90% of lung cancer is strongly associated with Tobacco smoking [<xref ref-type="bibr" rid="CR22">22</xref>]. Our results showed an estimated risk for lung cancer 6.7 times greater in Egyptian smokers than in non-smokers compared to 2.61 times in a previous study [<xref ref-type="bibr" rid="CR23">23</xref>] and an increased risk to develop lung cancer in males by 3.5-times than in females, which might be attributed to the higher incidence of smoking habit among males.</p><p>In our patients, three polymorphisms in <italic toggle="yes">CYP1A1</italic> gene were identified; <italic toggle="yes">CYP1A1*2C</italic> (I462V) was detected in 12.7% of control subjects and 11.4% of patients, and <italic toggle="yes">CYP1A1*4</italic> (T461N) identified in 22% of controls and 30.9% of patients. In one non-smoker adenocarcinoma patient, the rare <italic toggle="yes">CYP1A1</italic> 857&#160;T&#8201;&gt;&#8201;C (I286T) was identified. Ethnic difference in the distribution of <italic toggle="yes">CYP1A1*2C</italic> variant has been demonstrated in lung cancer patients, while few reports are available for <italic toggle="yes">CYP1A1*4.</italic> Frequencies of <italic toggle="yes">CYP1A1*2C</italic> ranged from 2.2% to 8.9% in Caucasians and was about 19.8% in Japanese, while <italic toggle="yes">CYP1A1*4</italic> allele was found in 2% to 5.7% of a Caucasian population [<xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref>]. Asian reports rarely observed presence of <italic toggle="yes">CYP1A1*4</italic> variant [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], meanwhile, it was more common among whites [<xref ref-type="bibr" rid="CR30">30</xref>] and it was reported, by itself, as a lung cancer risk factor in Caucasians [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>
<italic toggle="yes">CYP1A1*2C</italic> and *4 variants have generally been associated with moderate to high risk of lung cancer [<xref ref-type="bibr" rid="CR21">21</xref>]. These variants are rare in Caucasians and African-Americans. While studies of African-Americans have reported predominantly negative findings [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>], studies of Caucasians have been mixed [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Although I462V polymorphism is relatively frequent in Asian populations (18% to 25%), the Val allele is rare in Caucasian control populations, occurring in 7% to 13% of people [<xref ref-type="bibr" rid="CR35">35</xref>&#8211;<xref ref-type="bibr" rid="CR37">37</xref>] which agreed with obtained results in our control population (12.7%).</p><p>In the studied Egyptian population, combined variant T461N/ I462V (m2/m4) was found in 2.7% of lung cancer patients associated with 2-times higher risk to develop lung cancer compared to either control or individual m2 or m4 variant carriers.</p><p>In an Australian study to identify lung cancer-risk modifying <italic toggle="yes">CYP1A1</italic> haplotypes, *2A and *2C variants were significantly over-represented in NSCLC cases compared to controls, whereas *4 variant was under-represented. <italic toggle="yes">CYP1A1</italic> haplotypes (in allele order <italic toggle="yes">CYP1A1*4, *2C, *2A</italic>); CGC and CG associated with increased risk of lung cancer confirming CYP1A1 polymorphisms as minor risk factor for NSCLC. It was reported that <italic toggle="yes">CYP1A1*2C</italic> increase the overall risk of NSCLC with an odd ratio of 2.88 (95% CI&#8201;=&#8201;1.70&#8211;5.00, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR38">38</xref>], in accordance with our results in which <italic toggle="yes">CYP1A1*4</italic> and *2C associated with increased risk of NSCLC by 2 times. On the other hand, San Jose et al. reported that I462V and T461V increase the risk to lung cancer in Spanish population, especially to SCLC [<xref ref-type="bibr" rid="CR12">12</xref>]. Hung et al. found that I462V associated with higher risk for lung cancer, especially for lung adenocarcinoma [<xref ref-type="bibr" rid="CR39">39</xref>]. Song et al. noted significantly higher risk of lung cancer for I462V variant allele, even in the heterozygous form. However, this elevated risk was restricted to squamous cell carcinoma only, not for adenocarcinoma or other histological types of lung cancer [<xref ref-type="bibr" rid="CR21">21</xref>]. In our study, no significant difference of lung cancer risk for variant alleles between different pathological subtypes of NSCLC. We could not demonstrate a role of CYP1A1on the stage or the prognosis of the disease, in agreement with a previous study in Taiwan [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p>Controversial results were obtained from previous studies on interaction of smoking and <italic toggle="yes">CYP1A1</italic> variants. In the present study <italic toggle="yes">CYP1A1*1</italic>, wild type, was statistically more frequent among smoker controls. There was no association demonstrated between the heterozygous alleles of <italic toggle="yes">CYP1A1</italic> variants, smoking or smoking heaviness in prediction of lung cancer, 75% (3 of 4) of <italic toggle="yes">CYP1A1</italic> combined variant (T461N/ I462V) carriers were non-smokers.</p><p>Smoking was identified as a predominant risk factor and <italic toggle="yes">CYP1A1</italic>*<italic toggle="yes">2A</italic> polymorphism significantly associated with increased lung cancer risk (OR&#8201;=&#8201;1.69; 95% CI&#8201;=&#8201;1.11&#8211;2.59, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01), whereas <italic toggle="yes">CYP1A1</italic>*2A and *2C and Ile105Val imparted increased risk in non-smokers only [<xref ref-type="bibr" rid="CR41">41</xref>]. Though, Wenzlaff et al. found no significant association with any of <italic toggle="yes">CYP1A1</italic> variants in never smokers [<xref ref-type="bibr" rid="CR42">42</xref>], a recent pooled analysis by Hung et al. reported more than 2-fold increase in lung cancer susceptibility for both <italic toggle="yes">CYP1A1</italic>*2B and *2C variants among non-smoker Caucasians [<xref ref-type="bibr" rid="CR39">39</xref>]. According to Song et al., non-smokers with <italic toggle="yes">CYP1A1</italic>*2A variant had elevated risk than those homozygous for wild type alleles [<xref ref-type="bibr" rid="CR21">21</xref>]. Previous study in life-time non-smoking Chinese women reported an elevated risk of lung cancer for both <italic toggle="yes">CYP1A1</italic>*<italic toggle="yes">2B</italic> and *<italic toggle="yes">2C</italic> homozygous genotypes, furthermore, lung cancer risk associated with both polymorphisms was higher in women with lower environmental tobacco smoke exposure [<xref ref-type="bibr" rid="CR43">43</xref>]. I462V polymorphism is not related to lung cancer overall, but it might play a role at lower levels of Tobacco smoking among subjects with impaired carcinogen detoxification [<xref ref-type="bibr" rid="CR44">44</xref>].</p></sec><sec id="Sec10" sec-type="conclusion"><title>Conclusion</title><p>Beside the wild type <italic toggle="yes">CYP1A1</italic>*1, three variants of CYP1A1 gene were identified in Egyptian population; <italic toggle="yes">CYP1A1*2C, CYP1A1*4</italic> and the rare <italic toggle="yes">CYP1A1 c.857&#160;T&#8201;&gt;&#8201;C</italic> (<italic toggle="yes">I286T</italic>). Combined variant <italic toggle="yes">CYP1A1</italic>*2C/ <italic toggle="yes">CYP1A1*4</italic> associated with higher risk of lung cancer specially NSCLC among non-smokers. Identification of these variants may help in risk assessment, early detection and improvement of current treatment options for lung cancer patients. Further studies to clarify the role of these variants in the pathogenesis of the disease are needed.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>Asn</term><def><p>Asparagines</p></def></def-item><def-item><term>CYP</term><def><p>Cytochrome P450</p></def></def-item><def-item><term>GST</term><def><p>Glutathione S-transferase</p></def></def-item><def-item><term>Ile</term><def><p>Isoleucine</p></def></def-item><def-item><term>NAT</term><def><p>N-acetyltransferase</p></def></def-item><def-item><term>NSCLC</term><def><p>Non-small cell lung cancer</p></def></def-item><def-item><term>PAH</term><def><p>Polycyclic aromatic hydrocarbons</p></def></def-item><def-item><term>SCLC</term><def><p>Small cell lung cancer</p></def></def-item><def-item><term>Thr</term><def><p>Threonine</p></def></def-item><def-item><term>Val</term><def><p>Valine</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>Authors would like to thank STDF for the financial support of this work.</p><sec id="FPar1"><title>Funding</title><p>This work was funded by a grant from the Science and Technology Development Fund of Egypt (STDF), project ID 5016.</p></sec><sec id="FPar2"><title>Availability of data and material</title><p>Not applicable.</p></sec><sec id="FPar3"><title>Authors&#8217; contributions</title><p>NE designed the study, AD and AE collected the samples, DE, MH, SA and MA performed the molecular analysis, AS analyzed the data, NE and DE wrote the paper. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>The study was approved by the ethics committee of National Research Center of Egypt and informed consent was obtained from all participants.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soria</surname><given-names>JC</given-names></name><name name-style="western"><surname>Kim</surname><given-names>ES</given-names></name><name name-style="western"><surname>Fayette</surname><given-names>J</given-names></name><name name-style="western"><surname>Lantuejoul</surname><given-names>S</given-names></name><name name-style="western"><surname>Deutsch</surname><given-names>E</given-names></name><name name-style="western"><surname>Hong</surname><given-names>WK</given-names></name></person-group><article-title>Chemoprevention of lung cancer</article-title><source>Lancet Oncol</source><year>2003</year><volume>4</volume><issue>11</issue><fpage>659</fpage><pub-id pub-id-type="doi">10.1016/S1470-2045(03)01244-0</pub-id><pub-id pub-id-type="pmid">14602246</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breuer</surname><given-names>RH</given-names></name><name name-style="western"><surname>Postmus</surname><given-names>PE</given-names></name><name name-style="western"><surname>Smit</surname><given-names>EF</given-names></name></person-group><article-title>Molecular pathology of non-small-cell lung cancer</article-title><source>Respiration</source><year>2005</year><volume>72</volume><issue>3</issue><fpage>313</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1159/000085376</pub-id><pub-id pub-id-type="pmid">15942304</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouchardy</surname><given-names>C</given-names></name><name name-style="western"><surname>Benhamou</surname><given-names>S</given-names></name><name name-style="western"><surname>Jourenkova</surname><given-names>N</given-names></name><name name-style="western"><surname>Dayer</surname><given-names>P</given-names></name><name name-style="western"><surname>Hirvonen</surname><given-names>A</given-names></name></person-group><article-title>Metabolic genetic polymorphisms and susceptibility to lung cancer</article-title><source>Lung Cancer</source><year>2001</year><volume>32</volume><issue>2</issue><fpage>109</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/S0169-5002(00)00215-4</pub-id><pub-id pub-id-type="pmid">11325480</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>A</given-names></name><name name-style="western"><surname>Ingelman</surname><given-names>SM</given-names></name></person-group><article-title>Cytochrome P450 pharmacogenetics and cancer</article-title><source>J Oncogene</source><year>2006</year><volume>25</volume><issue>11</issue><fpage>1679</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209377</pub-id><pub-id pub-id-type="pmid">16550168</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lizasa</surname><given-names>T</given-names></name><name name-style="western"><surname>Baba</surname><given-names>M</given-names></name><name name-style="western"><surname>Saitoh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M</given-names></name><name name-style="western"><surname>Haga</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lyoda</surname><given-names>A</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H</given-names></name><name name-style="western"><surname>Hiroshima</surname><given-names>K</given-names></name><name name-style="western"><surname>Itoga</surname><given-names>S</given-names></name><name name-style="western"><surname>Tomonaga</surname><given-names>T</given-names></name><name name-style="western"><surname>Nomura</surname><given-names>F</given-names></name><name name-style="western"><surname>Fujisawa</surname><given-names>T</given-names></name></person-group><article-title>polymorphism in the 5 'flanking region of the CYP2E1 gene and elevated lung adenocarcinoma risk in a Japanese population</article-title><source>J Oncol Rep</source><year>2005</year><volume>14</volume><issue>4</issue><fpage>919</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">16142352</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimada</surname><given-names>T</given-names></name><name name-style="western"><surname>Yun</surname><given-names>CH</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>H</given-names></name><name name-style="western"><surname>Gautier</surname><given-names>JC</given-names></name><name name-style="western"><surname>Beaune</surname><given-names>PH</given-names></name><name name-style="western"><surname>Guengerich</surname><given-names>FP</given-names></name></person-group><article-title>Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens</article-title><source>Mol Pharmacol</source><year>1992</year><volume>41</volume><issue>5</issue><fpage>856</fpage><lpage>864</lpage><pub-id pub-id-type="pmid">1588920</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartsch</surname><given-names>H</given-names></name><name name-style="western"><surname>Petruzzelli</surname><given-names>S</given-names></name><name name-style="western"><surname>De Flora</surname><given-names>S</given-names></name><name name-style="western"><surname>Hietanen</surname><given-names>E</given-names></name><name name-style="western"><surname>Camus</surname><given-names>AM</given-names></name><name name-style="western"><surname>Castegnaro</surname><given-names>M</given-names></name><name name-style="western"><surname>Alexandrov</surname><given-names>K</given-names></name><name name-style="western"><surname>Rojas</surname><given-names>M</given-names></name><name name-style="western"><surname>Saracci</surname><given-names>R</given-names></name><name name-style="western"><surname>Giuntini</surname><given-names>C</given-names></name></person-group><article-title>Carcinogen metabolism in human lung tissues and the effect of tobacco smoking: results from a case&#8211;control multicenter study on lung cancer patients</article-title><source>Environ Health Perspect</source><year>1992</year><volume>98</volume><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">1336722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1289/ehp.9298119</pub-id><pub-id pub-id-type="pmcid">PMC1519605</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kouri</surname><given-names>RE</given-names></name><name name-style="western"><surname>McKinney</surname><given-names>CE</given-names></name><name name-style="western"><surname>Slomiany</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Snodgrass</surname><given-names>DR</given-names></name><name name-style="western"><surname>Wray</surname><given-names>NP</given-names></name><name name-style="western"><surname>McLemore</surname><given-names>TL</given-names></name></person-group><article-title>Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes</article-title><source>Cancer Res</source><year>1982</year><volume>42</volume><issue>12</issue><fpage>5030</fpage><lpage>5037</lpage><pub-id pub-id-type="pmid">6291746</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuzick</surname><given-names>J</given-names></name><name name-style="western"><surname>Routledge</surname><given-names>MN</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>D</given-names></name><name name-style="western"><surname>Garner</surname><given-names>RC</given-names></name></person-group><article-title>DNA adducts in different tissues of smokers and non-smokers</article-title><source>Int J Cancer</source><year>1990</year><volume>45</volume><issue>4</issue><fpage>673</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1002/ijc.2910450417</pub-id><pub-id pub-id-type="pmid">2323844</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>DH</given-names></name><name name-style="western"><surname>Schoket</surname><given-names>B</given-names></name><name name-style="western"><surname>Hewer</surname><given-names>A</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>E</given-names></name><name name-style="western"><surname>Kostic</surname><given-names>S</given-names></name><name name-style="western"><surname>Vincze</surname><given-names>I</given-names></name></person-group><article-title>Influence of cigarette smoking on the levels of DNA adducts in human bronchial epithelium and white blood cells</article-title><source>Int J Cancer</source><year>1990</year><volume>46</volume><issue>4</issue><fpage>569</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1002/ijc.2910460403</pub-id><pub-id pub-id-type="pmid">2210880</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anttila</surname><given-names>S</given-names></name><name name-style="western"><surname>Vainio</surname><given-names>H</given-names></name><name name-style="western"><surname>Hietanen</surname><given-names>E</given-names></name><name name-style="western"><surname>Camus</surname><given-names>AM</given-names></name><name name-style="western"><surname>Malaveille</surname><given-names>C</given-names></name><name name-style="western"><surname>Brun</surname><given-names>G</given-names></name><name name-style="western"><surname>Husgafvel-Pursiainen</surname><given-names>K</given-names></name><name name-style="western"><surname>Heikkila</surname><given-names>L</given-names></name><name name-style="western"><surname>Karjalainen</surname><given-names>A</given-names></name><name name-style="western"><surname>Bartsch</surname><given-names>H</given-names></name></person-group><article-title>Immunohistochemical detection of pulmonary cytochrome P450IA and metabolic activities associated with P450IA1 and P450IA2 isozymes in lung cancer patients</article-title><source>Environ Health Perspect</source><year>1992</year><volume>98</volume><fpage>179</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1289/ehp.9298179</pub-id><pub-id pub-id-type="pmid">1336724</pub-id><pub-id pub-id-type="pmcid">PMC1519621</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>San Jose</surname><given-names>C</given-names></name><name name-style="western"><surname>Cabanillas</surname><given-names>A</given-names></name><name name-style="western"><surname>Benitez</surname><given-names>J</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>JA</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>M</given-names></name><name name-style="western"><surname>Gervasini</surname><given-names>G</given-names></name></person-group><article-title>CYP1A1 gene polymorphisms increase lung cancer risk in a high-incidence region of Spain: a case control study</article-title><source>BMC Cancer</source><year>2010</year><volume>10</volume><fpage>463</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-10-463</pub-id><pub-id pub-id-type="pmid">20804547</pub-id><pub-id pub-id-type="pmcid">PMC2940803</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garte</surname><given-names>S</given-names></name><name name-style="western"><surname>Gaspari</surname><given-names>L</given-names></name><name name-style="western"><surname>Alexandrie</surname><given-names>AK</given-names></name><name name-style="western"><surname>Ambrosone</surname><given-names>C</given-names></name><name name-style="western"><surname>Autrup</surname><given-names>H</given-names></name><name name-style="western"><surname>Autrup</surname><given-names>JL</given-names></name><name name-style="western"><surname>Baranova</surname><given-names>H</given-names></name><name name-style="western"><surname>Bathum</surname><given-names>L</given-names></name><name name-style="western"><surname>Benhamou</surname><given-names>S</given-names></name><name name-style="western"><surname>Boffetta</surname><given-names>P</given-names></name><name name-style="western"><surname>Bouchardy</surname><given-names>C</given-names></name><name name-style="western"><surname>Breskvar</surname><given-names>K</given-names></name><name name-style="western"><surname>Brockmoller</surname><given-names>J</given-names></name><name name-style="western"><surname>Cascorbi</surname><given-names>I</given-names></name><name name-style="western"><surname>Clapper</surname><given-names>ML</given-names></name><name name-style="western"><surname>Coutelle</surname><given-names>C</given-names></name><name name-style="western"><surname>Daly</surname><given-names>A</given-names></name><name name-style="western"><surname>Dell'Omo</surname><given-names>M</given-names></name><name name-style="western"><surname>Dolzan</surname><given-names>V</given-names></name><name name-style="western"><surname>Dresler</surname><given-names>CM</given-names></name></person-group><article-title>Metabolic gene polymorphism frequencies in control populations</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2001</year><volume>10</volume><issue>12</issue><fpage>1239</fpage><lpage>1248</lpage><pub-id pub-id-type="pmid">11751440</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Georgiadis</surname><given-names>P</given-names></name><name name-style="western"><surname>Topinka</surname><given-names>J</given-names></name><name name-style="western"><surname>Vlachodimitropoulos</surname><given-names>D</given-names></name><name name-style="western"><surname>Stoikidou</surname><given-names>M</given-names></name><name name-style="western"><surname>Gioka</surname><given-names>M</given-names></name><name name-style="western"><surname>Stephanou</surname><given-names>G</given-names></name><name name-style="western"><surname>Autrup</surname><given-names>H</given-names></name><name name-style="western"><surname>Demopoulos</surname><given-names>NA</given-names></name><name name-style="western"><surname>Katsouyanni</surname><given-names>K</given-names></name><name name-style="western"><surname>Sram</surname><given-names>R</given-names></name><name name-style="western"><surname>Kyrtopoulos</surname><given-names>SA</given-names></name></person-group><article-title>Interactions between CYP1A1 polymorphisms and exposure to environmental tobacco smoke in the modulation of lymphocyte bulky DNA adducts and chromosomal aberrations</article-title><source>Carcinogenesis</source><year>2005</year><volume>26</volume><issue>1</issue><fpage>93</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgh294</pub-id><pub-id pub-id-type="pmid">15459023</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>D</given-names></name><name name-style="western"><surname>Kisselev</surname><given-names>P</given-names></name><name name-style="western"><surname>Cascorbi</surname><given-names>I</given-names></name><name name-style="western"><surname>Schunck</surname><given-names>WH</given-names></name><name name-style="western"><surname>Roots</surname><given-names>I</given-names></name></person-group><article-title>Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8 -dihydrodiol by human CYP1A1 variants</article-title><source>Carcinogenesis</source><year>2001</year><volume>22</volume><issue>3</issue><fpage>453</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1093/carcin/22.3.453</pub-id><pub-id pub-id-type="pmid">11238186</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>CM</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>JE</given-names></name><name name-style="western"><surname>Colosimo</surname><given-names>ML</given-names></name><name name-style="western"><surname>Barr</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>McLachlan</surname><given-names>RE</given-names></name><name name-style="western"><surname>Yang</surname><given-names>IA</given-names></name><name name-style="western"><surname>Wynder</surname><given-names>EL</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>D</given-names></name></person-group><article-title>Smoking and lung cancer: scientific challenges and opportunities</article-title><source>Cancer Res</source><year>1994</year><volume>54</volume><fpage>5284</fpage><lpage>5295</lpage><pub-id pub-id-type="pmid">7923155</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>KM</given-names></name><name name-style="western"><surname>Kang</surname><given-names>D</given-names></name><name name-style="western"><surname>Clapper</surname><given-names>ML</given-names></name><name name-style="western"><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Ono-Kihara</surname><given-names>M</given-names></name><name name-style="western"><surname>Kiyohara</surname><given-names>C</given-names></name><name name-style="western"><surname>Min</surname><given-names>S</given-names></name><name name-style="western"><surname>Lan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Le Marchand</surname><given-names>L</given-names></name><name name-style="western"><surname>Lin</surname><given-names>P</given-names></name><name name-style="western"><surname>Lung</surname><given-names>ML</given-names></name><name name-style="western"><surname>Pinarbasi</surname><given-names>H</given-names></name><name name-style="western"><surname>Pisani</surname><given-names>P</given-names></name><name name-style="western"><surname>Srivatanakul</surname><given-names>P</given-names></name><name name-style="western"><surname>Seow</surname><given-names>A</given-names></name><name name-style="western"><surname>Sugimura</surname><given-names>H</given-names></name><name name-style="western"><surname>Tokudome</surname><given-names>S</given-names></name><name name-style="western"><surname>Yokota</surname><given-names>J</given-names></name><name name-style="western"><surname>Taioli</surname><given-names>E</given-names></name></person-group><article-title>CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2008</year><volume>17</volume><issue>5</issue><fpage>1120</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-07-2786</pub-id><pub-id pub-id-type="pmid">18463401</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexandrie</surname><given-names>AK</given-names></name><name name-style="western"><surname>Nyberg</surname><given-names>F</given-names></name><name name-style="western"><surname>Warholm</surname><given-names>M</given-names></name><name name-style="western"><surname>Rannug</surname><given-names>A</given-names></name></person-group><article-title>Influence of CYP1A1, GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on lung cancer risk in a Swedish population</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2004</year><volume>13</volume><issue>6</issue><fpage>908</fpage><lpage>914</lpage><pub-id pub-id-type="pmid">15184245</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pisani</surname><given-names>P</given-names></name><name name-style="western"><surname>Srivatanakul</surname><given-names>P</given-names></name><name name-style="western"><surname>Randerson-Moor</surname><given-names>J</given-names></name><name name-style="western"><surname>Vipasrinimit</surname><given-names>S</given-names></name><name name-style="western"><surname>Lalitwongsa</surname><given-names>S</given-names></name><name name-style="western"><surname>Rautio</surname><given-names>A</given-names></name><name name-style="western"><surname>Kraul</surname><given-names>H</given-names></name><name name-style="western"><surname>Kojo</surname><given-names>A</given-names></name><name name-style="western"><surname>Salmela</surname><given-names>E</given-names></name><name name-style="western"><surname>Pelkonen</surname><given-names>O</given-names></name></person-group><article-title>Interindividual variability of coumarin 7-hydroxylation in healthy volunteers</article-title><source>Pharmacogenetics</source><year>1992</year><volume>2</volume><fpage>227</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1097/00008571-199210000-00005</pub-id><pub-id pub-id-type="pmid">1306122</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bag</surname><given-names>A</given-names></name><name name-style="western"><surname>Jyala</surname><given-names>NS</given-names></name><name name-style="western"><surname>Bag</surname><given-names>N</given-names></name></person-group><article-title>Cytochrome P450 1A1 genetic polymorphisms as cancer biomarkers</article-title><source>Indian J Cancer</source><year>2015</year><volume>52</volume><fpage>479</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.4103/0019-509X.178380</pub-id><pub-id pub-id-type="pmid">26960452</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>N</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W</given-names></name><name name-style="western"><surname>Xing</surname><given-names>D</given-names></name><name name-style="western"><surname>Lin</surname><given-names>D</given-names></name></person-group><article-title>CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: A case- control study in China</article-title><source>Carcinogenesis</source><year>2001</year><volume>22</volume><fpage>11</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/carcin/22.1.11</pub-id><pub-id pub-id-type="pmid">11159735</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stavridse</surname><given-names>JC</given-names></name></person-group><article-title>Lung carcinogenesis: pivotal role of metals in tobacco smoke</article-title><source>Free Radic Biol Med</source><year>2006</year><volume>41</volume><fpage>1017</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2006.06.024</pub-id><pub-id pub-id-type="pmid">16962926</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ezzeldin</surname><given-names>N</given-names></name><name name-style="western"><surname>El-Lebedy</surname><given-names>D</given-names></name><name name-style="western"><surname>Darwish</surname><given-names>A</given-names></name><name name-style="western"><surname>Ahmed El-Bastawissy</surname><given-names>A</given-names></name><name name-style="western"><surname>Shalaby</surname><given-names>A</given-names></name></person-group><article-title>Complement factor H polymorphism rs1061170 and the effect of cigarette smoking on the risk of lung cancer</article-title><source>Contemp Oncol (Pozn)</source><year>2015</year><volume>19</volume><issue>6</issue><fpage>441</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">26843839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5114/wo.2015.56202</pub-id><pub-id pub-id-type="pmcid">PMC4731447</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawajiri</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakachi</surname><given-names>K</given-names></name><name name-style="western"><surname>Imai</surname><given-names>K</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>J</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>S</given-names></name></person-group><article-title>The CYP1A1 gene and cancer susceptibility</article-title><source>Crit Rev Oncol Hematol</source><year>1993</year><volume>14</volume><fpage>77</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/1040-8428(93)90007-Q</pub-id><pub-id pub-id-type="pmid">8103989</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cascorbi</surname><given-names>I</given-names></name><name name-style="western"><surname>Brockmoller</surname><given-names>J</given-names></name><name name-style="western"><surname>Roots</surname><given-names>I</given-names></name></person-group><article-title>A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>4965</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8895751</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mrozikiewicz</surname><given-names>PM</given-names></name><name name-style="western"><surname>Cascorbi</surname><given-names>I</given-names></name><name name-style="western"><surname>Brockmoller</surname><given-names>J</given-names></name><name name-style="western"><surname>Roots</surname><given-names>I</given-names></name></person-group><article-title>CYP1A1 mutations 4887A, 4889G, 5639C and 6235C in the Polish population and their allelic linkage, determined by peptide nucleic acid-mediated PCR clamping</article-title><source>Pharmacogenetics</source><year>1997</year><volume>7</volume><fpage>303</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/00008571-199708000-00005</pub-id><pub-id pub-id-type="pmid">9295058</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aynacioglu</surname><given-names>AS</given-names></name><name name-style="western"><surname>Cascorbi</surname><given-names>I</given-names></name><name name-style="western"><surname>Mrozikiewicz</surname><given-names>PM</given-names></name><name name-style="western"><surname>Roots</surname><given-names>I</given-names></name></person-group><article-title>High frequency of CYP1A1 mutations in a Turkish population</article-title><source>Arch Toxicol</source><year>1998</year><volume>72</volume><fpage>215</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s002040050491</pub-id><pub-id pub-id-type="pmid">9587016</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duell</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Holly</surname><given-names>EA</given-names></name><name name-style="western"><surname>Bracci</surname><given-names>PM</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Wiencke</surname><given-names>JK</given-names></name><name name-style="western"><surname>Kelsey</surname><given-names>KT</given-names></name></person-group><article-title>A population-based, case&#8211;control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk</article-title><source>J Natl Cancer Inst</source><year>2002</year><volume>94</volume><fpage>297</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1093/jnci/94.4.297</pub-id><pub-id pub-id-type="pmid">11854392</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaffi</surname><given-names>SM</given-names></name><name name-style="western"><surname>Shah</surname><given-names>MA</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>IA</given-names></name><name name-style="western"><surname>Koul</surname><given-names>P</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>SN</given-names></name><name name-style="western"><surname>Siddiqi</surname><given-names>MA</given-names></name></person-group><article-title>CYP1A1 polymorphisms and risk of lung cancer in the ethnic Kashmiri population</article-title><source>Asian Pac J Cancer Prev</source><year>2009</year><volume>10</volume><fpage>651</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19827888</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Millikan</surname><given-names>RC</given-names></name><name name-style="western"><surname>Bell</surname><given-names>DA</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L</given-names></name><name name-style="western"><surname>Tse</surname><given-names>CK</given-names></name><name name-style="western"><surname>Newman</surname><given-names>B</given-names></name><name name-style="western"><surname>Conway</surname><given-names>K</given-names></name></person-group><article-title>Polychlorinated biphenyls, cytochrome P450 1A1 (CYP1A1) polymorphisms, and breast cancer risk among African American women and white women in North Carolina: A population-based case&#8211;control study</article-title><source>Breast Cancer Res</source><year>2005</year><volume>7</volume><fpage>R12</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1186/bcr941</pub-id><pub-id pub-id-type="pmid">15642161</pub-id><pub-id pub-id-type="pmcid">PMC1064095</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishibe</surname><given-names>N</given-names></name><name name-style="western"><surname>Wiencke</surname><given-names>JK</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>ZF</given-names></name><name name-style="western"><surname>McMillan</surname><given-names>A</given-names></name><name name-style="western"><surname>Spitz</surname><given-names>M</given-names></name><name name-style="western"><surname>Kelsey</surname><given-names>KT</given-names></name></person-group><article-title>Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans</article-title><source>Cancer Epidemiol Biomarkers Prev.</source><year>1997</year><volume>6</volume><fpage>1075</fpage><lpage>1080</lpage><pub-id pub-id-type="pmid">9419406</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taioli</surname><given-names>E</given-names></name><name name-style="western"><surname>Ford</surname><given-names>J</given-names></name><name name-style="western"><surname>Trachman</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Demopoulos</surname><given-names>R</given-names></name><name name-style="western"><surname>Garte</surname><given-names>S</given-names></name></person-group><article-title>Lung cancer risk and CYP1A1 genotype in African Americans</article-title><source>Carcinogenesis</source><year>1998</year><volume>19</volume><fpage>813</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1093/carcin/19.5.813</pub-id><pub-id pub-id-type="pmid">9635868</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Closas</surname><given-names>M</given-names></name><name name-style="western"><surname>Kelsey</surname><given-names>KT</given-names></name><name name-style="western"><surname>Wiencke</surname><given-names>JK</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wain</surname><given-names>JC</given-names></name><name name-style="western"><surname>Christiani</surname><given-names>DC</given-names></name></person-group><article-title>A case&#8211;control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility (Massachusetts, United States)</article-title><source>Cancer Causes Control</source><year>1997</year><volume>8</volume><fpage>544</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1023/A:1018481910663</pub-id><pub-id pub-id-type="pmid">9242469</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dresler</surname><given-names>CM</given-names></name><name name-style="western"><surname>Fratelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Babb</surname><given-names>J</given-names></name><name name-style="western"><surname>Everley</surname><given-names>L</given-names></name><name name-style="western"><surname>Evans</surname><given-names>AA</given-names></name><name name-style="western"><surname>Clapper</surname><given-names>ML</given-names></name></person-group><article-title>Gender differences in genetic susceptibility for lung cancer</article-title><source>Lung Cancer</source><year>2000</year><volume>30</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/S0169-5002(00)00163-X</pub-id><pub-id pub-id-type="pmid">11137199</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>K</given-names></name><name name-style="western"><surname>Asao</surname><given-names>T</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>T</given-names></name></person-group><article-title>Ethnic-related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations</article-title><source>Xenobiotica</source><year>2000</year><volume>30</volume><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1080/004982500237677</pub-id><pub-id pub-id-type="pmid">10752643</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>XR</given-names></name><name name-style="western"><surname>Wacholder</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Dean</surname><given-names>M</given-names></name><name name-style="western"><surname>Clark</surname><given-names>V</given-names></name><name name-style="western"><surname>Gold</surname><given-names>B</given-names></name><name name-style="western"><surname>Brown</surname><given-names>LM</given-names></name><name name-style="western"><surname>Stone</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Fraumeni</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Caporaso</surname><given-names>NE</given-names></name></person-group><article-title>CYP1A1 and GSTM1 polymorphisms in relation to lung cancer risk in Chinese women</article-title><source>Cancer Lett</source><year>2004</year><volume>214</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2004.06.040</pub-id><pub-id pub-id-type="pmid">15363546</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chowbay</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EJ</given-names></name></person-group><article-title>An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore</article-title><source>Drug Metab Rev</source><year>2005</year><volume>37</volume><fpage>327</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1081/DMR-28805</pub-id><pub-id pub-id-type="pmid">15931768</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsen</surname><given-names>JE</given-names></name><name name-style="western"><surname>ColosimoML</surname><given-names>YIA</given-names></name><name name-style="western"><surname>Bowman</surname><given-names>R</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>PV</given-names></name><name name-style="western"><surname>Fong</surname><given-names>KM</given-names></name></person-group><article-title>CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung</article-title><source>Carcinogenesis</source><year>2006</year><volume>27</volume><fpage>525</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgi227</pub-id><pub-id pub-id-type="pmid">16195240</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Boffetta</surname><given-names>P</given-names></name><name name-style="western"><surname>Brockm&#246;ller</surname><given-names>J</given-names></name><name name-style="western"><surname>Butkiewicz</surname><given-names>D</given-names></name><name name-style="western"><surname>Cascorbi</surname><given-names>I</given-names></name><name name-style="western"><surname>Clapper</surname><given-names>ML</given-names></name><name name-style="western"><surname>Garte</surname><given-names>S</given-names></name><name name-style="western"><surname>Haugen</surname><given-names>A</given-names></name><name name-style="western"><surname>Hirvonen</surname><given-names>A</given-names></name><name name-style="western"><surname>Anttila</surname><given-names>S</given-names></name><name name-style="western"><surname>Kalina</surname><given-names>I</given-names></name><name name-style="western"><surname>Le Marchand</surname><given-names>L</given-names></name><name name-style="western"><surname>London</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Rannug</surname><given-names>A</given-names></name><name name-style="western"><surname>Romkes</surname><given-names>M</given-names></name><name name-style="western"><surname>Salagovic</surname><given-names>J</given-names></name><name name-style="western"><surname>Schoket</surname><given-names>B</given-names></name><name name-style="western"><surname>Gaspari</surname><given-names>L</given-names></name><name name-style="western"><surname>Taioli</surname><given-names>E</given-names></name></person-group><article-title>CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis</article-title><source>Carcinogenesis</source><year>2003</year><volume>24</volume><fpage>875</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgg026</pub-id><pub-id pub-id-type="pmid">12771031</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>YC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>SK</given-names></name><name name-style="western"><surname>Chang</surname><given-names>YY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>P</given-names></name></person-group><article-title>Influence of polymorphism at p53, CYP1A1 and GSTM1 loci on p53 mutation and association of p53 mutation with prognosis in lung cancer</article-title><source>Zhonghua Yi Xue Za Zhi (Taipei)</source><year>1999</year><volume>62</volume><issue>7</issue><fpage>402</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">10418172</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ihsan</surname><given-names>R</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>PS</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>AK</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>DS</given-names></name><name name-style="western"><surname>Kaushal</surname><given-names>M</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>JD</given-names></name><name name-style="western"><surname>Zomawia</surname><given-names>E</given-names></name><name name-style="western"><surname>Verma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kapur</surname><given-names>S</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>S</given-names></name></person-group><article-title>Multiple Analytical Approaches Reveal Distinct Gene-Environment Interactions in Smokers and Non Smokers in Lung Cancer</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><issue>12</issue><fpage>e29431</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0029431</pub-id><pub-id pub-id-type="pmid">22206016</pub-id><pub-id pub-id-type="pmcid">PMC3242784</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wenzlaff</surname><given-names>AS</given-names></name><name name-style="western"><surname>Cote</surname><given-names>ML</given-names></name><name name-style="western"><surname>Bock</surname><given-names>CH</given-names></name><name name-style="western"><surname>Land</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Santer</surname><given-names>SK</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>DR</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>AG</given-names></name></person-group><article-title>CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study</article-title><source>Carcinogenesis</source><year>2005</year><volume>26</volume><issue>12</issue><fpage>2207</fpage><lpage>2212</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgi191</pub-id><pub-id pub-id-type="pmid">16051642</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>DP</given-names></name><name name-style="western"><surname>Tan</surname><given-names>KW</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B</given-names></name><name name-style="western"><surname>Seow</surname><given-names>A</given-names></name></person-group><article-title>CYP1A1 polymorphisms and risk of lung cancer in non-smoking Chinese women: Influence of environmental tobacco smoke exposure and GSTM1/T1 genetic variation</article-title><source>Cancer Causes Control</source><year>2005</year><volume>16</volume><fpage>399</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1007/s10552-004-5476-0</pub-id><pub-id pub-id-type="pmid">15953982</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>London</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Coetzee</surname><given-names>GA</given-names></name><name name-style="western"><surname>Gao</surname><given-names>YT</given-names></name><name name-style="western"><surname>Ross</surname><given-names>RK</given-names></name><name name-style="western"><surname>Yu</surname><given-names>MC</given-names></name></person-group><article-title>CYP1A1 I462V genetic polymorphism and lung cancer risk in a cohort of men in Shanghai, China</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2000</year><volume>9</volume><issue>9</issue><fpage>987</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">11008920</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>